Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhNGF in Moderate to Severe Dry Eye
NCT03982368Phase 2Completed
- Sponsor
- Dompé
- Start
- Jun 2019
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cenegermin in dry eye syndrome (DED) (3 arms), sponsored by Dompé. Primary endpoint: Change From Baseline in Schirmer I Test (Without Anesthesia) at 4 weeks. Started Jun 2019; status: completed.
02
Drugs
cenegermin
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT03982368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03982368.